Table of Contents Author Guidelines Submit a Manuscript
International Journal of Hepatology
Volume 2013 (2013), Article ID 103830, 10 pages
http://dx.doi.org/10.1155/2013/103830
Research Article

Enhanced Antitumor Activity with Combining Effect of mTOR Inhibition and Microtubule Stabilization in Hepatocellular Carcinoma

1Department of Clinical Oncology, The Chinese University of Hong Kong, Hong Kong
2Cancer Drug Testing Unit, State Key Laboratory of Oncology in South China, Hong Kong Cancer Institute and Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Hong Kong
3Department of Otolaryngology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA

Received 20 November 2012; Accepted 4 January 2013

Academic Editor: Bin Lu

Copyright © 2013 Qian Zhou et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. He, D. Gu, X. Wu et al., “Major causes of death among men and women in China,” New England Journal of Medicine, vol. 353, no. 11, pp. 1124–1134, 2005. View at Publisher · View at Google Scholar · View at Scopus
  2. D. M. Parkin, “Global cancer statistics in the year 2000,” Lancet Oncology, vol. 2, no. 9, pp. 533–543, 2001. View at Publisher · View at Google Scholar · View at Scopus
  3. M. Schwartz, “Liver transplantation for hepatocellular carcinoma,” Gastroenterology, vol. 127, no. 5, supplement 1, pp. S268–S276, 2004. View at Publisher · View at Google Scholar · View at Scopus
  4. R. T. P. Poon, S. T. Fan, C. M. Lo et al., “Improving survival results after resection of hepatocellular carcinoma: a prospective study of 377 patients over 10 years,” Annals of Surgery, vol. 234, no. 1, pp. 63–70, 2001. View at Publisher · View at Google Scholar · View at Scopus
  5. A. L. Cheng, Y. K. Kang, Z. Chen et al., “Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial,” The Lancet Oncology, vol. 10, no. 1, pp. 25–34, 2009. View at Publisher · View at Google Scholar · View at Scopus
  6. J. M. Llovet, S. Ricci, V. Mazzaferro et al., “Sorafenib in advanced hepatocellular carcinoma,” New England Journal of Medicine, vol. 359, no. 4, pp. 378–390, 2008. View at Publisher · View at Google Scholar · View at Scopus
  7. M. A. Bjornsti and P. J. Houghton, “The TOR pathway: a target for cancer therapy,” Nature Reviews Cancer, vol. 4, no. 5, pp. 335–348, 2004. View at Google Scholar · View at Scopus
  8. S. S. Agarwala and S. Case, “Everolimus (RAD001) in the treatment of advanced renal cell carcinoma: a review,” Oncologist, vol. 15, no. 3, pp. 236–245, 2010. View at Publisher · View at Google Scholar · View at Scopus
  9. K. L. Yim, “Everolimus and mTOR inhibition in pancreatic neuroendocrine tumors,” Cancer Management and Research, vol. 4, pp. 207–214, 2012. View at Google Scholar
  10. J. Baselga, M. Campone, M. Piccart et al., “Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer,” New England Journal of Medicine, vol. 366, no. 6, pp. 520–529, 2012. View at Publisher · View at Google Scholar
  11. M. P. Curran, “Everolimus: in patients with subependymal giant cell astrocytoma associated with tuberous sclerosis complex,” Pediatric Drugs, vol. 14, no. 1, pp. 51–60, 2012. View at Publisher · View at Google Scholar
  12. L. S. Blaszkowsky, T. A. Abrams, R. A. Miksad et al., “Phase I/II study of everolimus in patients with advanced hepatocellular carcinoma (HCC),” Journal of Clinical Oncology, ASCO Annual Meeting, Article ID e14542, 2010. View at Google Scholar
  13. S. Mabuchi, D. A. Altomare, D. C. Connolly et al., “RAD001 (Everolimus) delays tumor onset and progression in a transgenic mouse model of ovarian cancer,” Cancer Research, vol. 67, no. 6, pp. 2408–2413, 2007. View at Publisher · View at Google Scholar · View at Scopus
  14. C. Wu, M. Wangpaichitr, L. Feun et al., “Overcoming cisplatin resistance by mTOR inhibitor in lung cancer,” Molecular Cancer, vol. 4, article 25, 2005. View at Publisher · View at Google Scholar · View at Scopus
  15. M. A. Patil, M. S. Chua, K. H. Pan et al., “An integrated data analysis approach to characterize genes highly expressed in hepatocellular carcinoma,” Oncogene, vol. 24, no. 23, pp. 3737–3747, 2005. View at Publisher · View at Google Scholar · View at Scopus
  16. C. Y. Tung, C. H. Jen, M. T. Hsu, H. W. Wang, and C. H. Lin, “A novel regulatory event-based gene set analysis method for exploring global functional changes in heterogeneous genomic data sets,” BMC Genomics, vol. 10, article 26, 2009. View at Publisher · View at Google Scholar · View at Scopus
  17. Q. Zhou, A. K. K. Ching, W. K. C. Leung et al., “Novel therapeutic potential in targeting microtubules by nanoparticle albumin-bound paclitaxel in hepatocellular carcinoma,” International Journal of Oncology, vol. 38, no. 3, pp. 721–731, 2011. View at Publisher · View at Google Scholar · View at Scopus
  18. L. S. Faried, A. Faried, T. Kanuma et al., “Inhibition of the mammalian target of rapamycin (mTOR) by rapamycin increases chemosensitivity of CaSki cells to paclitaxel,” European Journal of Cancer, vol. 42, no. 7, pp. 934–947, 2006. View at Publisher · View at Google Scholar · View at Scopus
  19. D. J. VanderWeele, R. Zhou, and C. M. Rudin, “Akt up-regulation increases resistance to microtubule-directed chemotherapeutic agents through mammalian target of rapamycin,” Molecular Cancer Therapeutics, vol. 3, no. 12, pp. 1605–1613, 2004. View at Google Scholar · View at Scopus
  20. Q. Zhou, V. W. Lui, C. P. Lau et al., “Sustained antitumor activity by co-targeting mTOR and the microtubule with temsirolimus/vinblastine combination in hepatocellular carcinoma,” Biochemical Pharmacology, vol. 83, no. 9, pp. 1146–1158, 2012. View at Publisher · View at Google Scholar
  21. J. H. Nettles, H. Li, B. Cornett, J. M. Krahn, J. P. Snyder, and K. H. Downing, “The binding mode of epothilone A on α,β-tubulin by electron crystallography,” Science, vol. 305, no. 5685, pp. 866–869, 2004. View at Publisher · View at Google Scholar · View at Scopus
  22. K. H. Altmann, G. Bold, G. Caravatti et al., “Epothilones and their analogs—potential new weapons in the fight against cancer,” Chimia, vol. 54, no. 11, pp. 612–621, 2000. View at Google Scholar · View at Scopus
  23. R. J. Kowalski, P. Giannakakou, and E. Hamel, “Activities of the microtubule-stabilizing agents epothilones A and B with purified tubulin and in cells resistant to paclitaxel (Taxol),” Journal of Biological Chemistry, vol. 272, no. 4, pp. 2534–2541, 1997. View at Publisher · View at Google Scholar · View at Scopus
  24. T. S. K. Mok, E. Choi, D. Yau et al., “Effects of patupilone (epothilone B; EPO906), a novel chemotherapeutic agent, in hepatocellular carcinoma: an in vitro study,” Oncology, vol. 71, no. 3-4, pp. 292–296, 2007. View at Publisher · View at Google Scholar · View at Scopus
  25. E. H. Rubin, J. Rothermel, F. Tesfaye et al., “Phase I dose-finding study of weekly single-agent patupilone in patients with advanced solid tumors,” Journal of Clinical Oncology, vol. 23, no. 36, pp. 9120–9129, 2005. View at Publisher · View at Google Scholar · View at Scopus
  26. K. Osterlind, J. M. Sanchez, P. Zatloukal et al., “Phase I/II dose escalation trial of patupilone every 3 weeks in patients with non-small cell lung cancer,” Journal of Clinical Oncology, vol. 23, no. 16, p. 647S, 2005. View at Google Scholar
  27. W. M. Smit, J. Sufliarsky, S. Spanik et al., “Phase I/II dose-escalation trial of patupilone every 3 weeks in patients with resistant/refractory ovarian cancer,” European Journal of Cancer, vol. 3, no. 2, pp. 261–262, 2005. View at Google Scholar
  28. V. W. Y. Lui, A. L. Boehm, P. Koppikar et al., “Antiproliferative mechanisms of a transcription factor decoy targeting signal transducer and activator of transcription (STAT) 3: the role of STAT1,” Molecular Pharmacology, vol. 71, no. 5, pp. 1435–1443, 2007. View at Publisher · View at Google Scholar · View at Scopus
  29. V. W. Y. Lui, D. M. Yau, E. Y. Wong et al., “Cucurbitacin I elicits anoikis sensitization, inhibits cellular invasion and in vivo tumor formation ability of nasopharyngeal carcinoma cells,” Carcinogenesis, vol. 30, no. 12, pp. 2085–2094, 2009. View at Publisher · View at Google Scholar · View at Scopus
  30. V. W. Y. Lui, D. M. S. Yau, C. S. F. Cheung et al., “FGF8b oncogene mediates proliferation and invasion of Epstein-Barr virus-associated nasopharyngeal carcinoma cells: implication for viral-mediated FGF8b upregulation,” Oncogene, vol. 30, no. 13, pp. 1518–1530, 2011. View at Publisher · View at Google Scholar · View at Scopus
  31. L. Hu, J. Hofmann, Y. Lu, G. B. Mills, and R. B. Jaffe, “Inhibition of phosphatidylinositol 3′-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models,” Cancer Research, vol. 62, no. 4, pp. 1087–1092, 2002. View at Google Scholar · View at Scopus
  32. T. C. Chou, X. G. Zhang, A. Balog et al., “Desoxyepothilone B: an efficacious microtubule-targeted antitumor agent with a promising in vivo profile relative to epothilone B,” Proceedings of the National Academy of Sciences of the United States of America, vol. 95, no. 16, pp. 9642–9647, 1998. View at Publisher · View at Google Scholar · View at Scopus
  33. K. H. Tam, Z. F. Yang, C. K. Lau, C. T. Lam, R. W. C. Pang, and R. T. P. Poon, “Inhibition of mTOR enhances chemosensitivity in hepatocellular carcinoma,” Cancer Letters, vol. 273, no. 2, pp. 201–209, 2009. View at Publisher · View at Google Scholar · View at Scopus
  34. L. Wang, W. Y. Shi, Z. Y. Wu et al., “Cytostatic and anti-angiogenic effects of temsirolimus in refractory mantle cell lymphoma,” Journal of Hematology & Oncology, vol. 3, article 30, 2010. View at Publisher · View at Google Scholar
  35. T. S. K. Mok, E. Choi, D. Yau et al., “Effects of patupilone (epothilone B; EPO906), a novel chemotherapeutic agent, in hepatocellular carcinoma: an in vitro study,” Oncology, vol. 71, no. 3-4, pp. 292–296, 2007. View at Publisher · View at Google Scholar · View at Scopus
  36. D. Marimpietri, C. Brignole, B. Nico et al., “Combined therapeutic effects of vinblastine and rapamycin on human neuroblastoma growth, apoptosis, and angiogenesis,” Clinical Cancer Research, vol. 13, no. 13, pp. 3977–3988, 2007. View at Publisher · View at Google Scholar · View at Scopus
  37. N. Campostrini, D. Marimpietri, A. Totolo et al., “Proteomic analysis of anti-angiogenic effects by a combined treatment with vinblastine and rapamycin in an endothelial cell line,” Proteomics, vol. 6, no. 15, pp. 4420–4431, 2006. View at Publisher · View at Google Scholar · View at Scopus
  38. A. X. Zhu, T. A. Abrams, R. Miksad et al., “Phase 1/2 study of everolimus in advanced hepatocellular carcinoma,” Cancer, vol. 117, no. 22, pp. 5094–5102, 2011. View at Publisher · View at Google Scholar
  39. A. P. Venook, R. Poon, Y. K. Kang et al., “Evaluation of patupilone as monotherapy in patients with advanced hepatocellular carcinoma (HCC),” Journal of Clinical Oncology, vol. 25, ASCO Annual Meeting Proceedings, no. 18S, Article ID 15055, 2007. View at Google Scholar